Effect of imidapril and nifedipine on left ventricular hypertrophy in untreated hypertension

Clinical Drug Investigation

Volumn 25, Issue 6, 2005, Pages 367-375

  Sabharwal, Nikant Kumar ^a   Swinburn, Jonathan ^a   Lahiri, Avijit ^a   Senior, Roxy ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROCHLOROTHIAZIDE; IMIDAPRIL; NIFEDIPINE;

ADULT; AGE DISTRIBUTION; AGED; ARTERIAL PRESSURE; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; FEMALE; HEADACHE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART STROKE VOLUME; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HUMAN; HYPERTENSION; KIDNEY DISEASE; LEG EDEMA; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PARAMETER; PHLEBITIS; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; SUSTAINED RELEASE PREPARATION; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME;

EID: 22544438706     PISSN: 11732563     EISSN: 11732563     Source Type: Journal    
DOI: 10.2165/00044011-200525060-00002     Document Type: Article

References (36)

1. Demolis P, Annane D, Duhaze P, et al. Systemic, regional and cerebral hemodynamic effects of a new angiotensin converting enzyme inhibitor, imidapril, in healthy volunteers. Fundam Clin Pharmacol 1994; 8 (1): 80-9
2. Vandenburg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidapril, a new ACE inhibitor. Br J Clin Pharmacol 1994; 37 (3): 265-72
3. Harder S, Thurmann PA, Ungethum W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998; 45 (4): 377-80
4. Huang PJ, Chien KL, Chen MF, et al. Efficacy and safety of imidapril in patients with essential hypertension: a double-blind comparison with captopril. Cardiology 2001; 95 (3): 146-50
5. Saruta T, Omae T, Kuramochi M, et al. Imidapril hydrochloride in essential hypertension: a double-blind comparative study using enalapril maleate as a control. J Hypertens Suppl 1995; 13 Suppl. 3: 523-30
6. Saruta T, Arakawa K, Iimura O, et al. Difference in the incidence of cough induced by angiotensin converting enzyme inhibitors: a comparative study using imidapril hydrochloride and enalapril maleate. Hypertens Res 1999; 22 (3): 197-202
7. Dews I, VandenBurg M. A 24-week dose-titration study of the angiotensin-converting enzyme inhibitor imidapril in the treatment of mild-to-moderate essential hypertension in the elderly. J Int Med Res 2001; 29 (2): 100-7
8. Hoogkamer JF, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 1997; 51 (6): 489-91
9. Hoogkamer JF, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure. Eur J Clin Pharmacol 1998; 54 (1): 59-61
10. Kohno I, Ijiri H, Takusagawa M, et al. Effect of imidapril in dipper and nondipper hypertensive patients: comparison between morning and evening administration. Chronobiol Int 2000; 17 (2): 209-19
11. Oshima S, Ogawa H, Mizuno Y, et al. The effects of the angiotensin-converting enzyme inhibitor imidapril on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction. Am Heart J 1997; 134 (5 Pt 1): 961-6
12. Soejima H, Ogawa H, Yasue H, et al. Effects of imidapril therapy on endogenous fibrinolysis in patients with recent myocardial infarction. Clin Cardiol 1997; 20 (5): 441-5
13. Pinto YM, van Veldhuisen DJ, Tjon KJR, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996; 50 (4): 265-8
14. Sasaguri M, Noda K, Tashiro E, et al. The regression of left ventricular hypertrophy by imidapril and the reduction of serum procollagen type III amino-terminal peptide in hypertensive patients. Hypertens Res 2000; 23 (4): 317-22
15. Devereux RB, Lutas EM, Casale PN, et al. Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984; 4 (6): 1222-30
16. Kannel WB, Gordon T, Castelli WP, et al. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham Study. Ann Intern Med 1970; 72 (6): 813-22
17. Levy D, Labib SB, Anderson KM, et al. Determinants of sensitivity and specificity of electrocardiographic criteria for left ventricular hypertrophy. Circulation 1990; 81 (3): 815-20
18. Savage DD, Levy D, Dannenberg AL, et al. Association of echocardiographic left ventricular mass with body size, blood pressure and physical activity (the Framingham Study). Am J Cardiol 1990; 65 (5): 371-6
19. Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation 1994; 90 (1): 179-85
20. Verdecchia P, Schillaci G, Guerrieri M, et al. Circadian blood pressure changes and left ventricular hypertrophy in essential hypertension. Circulation 1990; 81 (2): 528-36
21. Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105 (2): 173-8
22. Levy D, Garrison RJ, Savage DD, et al. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322 (22): 1561-6
23. Koren MJ, Devereux RB, Casale PN, et al. Relation of left ventricular mass and geometry to morbidity and mortality in uncomplicated essential hypertension. Ann Intern Med 1991; 114 (5): 345-52
24. Ghali JK, Liao Y, Simmons B, et al. The prognostic role of left ventricular hypertrophy in patients with or without coronary artery disease. Ann Intern Med 1992; 117 (10): 831-6
25. Schmieder RE, Messerli FH. Determinants of ventricular ectopy in hypertensive cardiac hypertrophy. Am Heart J 1992; 123 (1): 89-95
26. Schmieder RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension: a meta-analysis of randomized double-blind studies. JAMA 1996; 275 (19): 1507-13
27. Neaton JD, Grimm RHJ, Prineas RJ, et al. Treatment of Mild Hypertension Study. Final results: treatment of mild hypertension study research group. JAMA 1993; 270 (6): 713-24
28. Muiesan ML, Salvetti M, Rizzoni D, et al. Association of change in left ventricular mass with prognosis during long-term antihypertensive treatment. J Hypertens 1995; 13 (10): 1091-5
29. Verdecchia P, Schillaci G, Borgioni C, et al. Prognostic significance of serial changes in left ventricular mass in essential hypertension. Circulation 1998; 97 (1): 48-54
30. Dahlof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients: a metaanalysis of 109 treatment studies. Am J Hypertens 1992; 5 (2): 95-110
31. Leenen FH, Myers MG, Joyner CD, et al. Differential effects of once-daily antihypertensive drugs on blood pressure, left ventricular mass and sympathetic activity: nifedipine-GITS versus felodipine-ER versus enalapril. Can J Cardiol 2002; 18 (12): 1285-93
32. Midtvedt K, Hartmann A, Holdaas H, et al. Efficacy of nifedipine or lisinopril in the treatment of hypertension after parallel transplantation: a double-blind randomised comparative trial. Clin Transplant 2001; 15 (6): 426-31
33. Midtvedt K, Ihlen H, Hartmann A, et al. Reduction of left ventricular mass by lisinopril and nifedipine in hypertensive renal transplant recipients: a prospective randomized double-blind study. Transplantation 2001; 72 (1): 107-11
34. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting- enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators [published erratum appears in 2000 May 4; 342 (18): 1376]. N Engl J Med 2000; 342 (3): 145-53
35. Fox KM, EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003; 362 (9386): 782-8
36. van der Does R, Euler R. A randomized, double-blind, parallel-group study to compare the anti-hypertensive effects of imidapril and nifedipine in the treatment of mild-to-moderate essential hypertension. J Int Med Res 2001; 29 (3): 154-62